Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia
Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypot...
Saved in:
Published in | Psychiatry research Vol. 186; no. 1; pp. 23 - 27 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Kidlington
Elsevier Ireland Ltd
30.03.2011
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0165-1781 1872-7123 |
DOI | 10.1016/j.psychres.2010.07.049 |
Cover
Abstract | Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3
months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia. |
---|---|
AbstractList | Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia. Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia. Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3 months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia. Abstract Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3 months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia. |
Author | Sumiyoshi, Tomiki Higuchi, Yuko Suzuki, Michio Kurachi, Masayoshi Matsui, Mie Itoh, Toru Takamiya, Chieko Itoh, Hiroko Uehara, Takashi Arai, Hirofumi |
Author_xml | – sequence: 1 givenname: Tomiki surname: Sumiyoshi fullname: Sumiyoshi, Tomiki email: tomikisumiyoshi840@hotmail.com organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 2 givenname: Yuko surname: Higuchi fullname: Higuchi, Yuko organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 3 givenname: Mie surname: Matsui fullname: Matsui, Mie organization: Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan – sequence: 4 givenname: Hiroko surname: Itoh fullname: Itoh, Hiroko organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 5 givenname: Takashi surname: Uehara fullname: Uehara, Takashi organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 6 givenname: Toru surname: Itoh fullname: Itoh, Toru organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 7 givenname: Hirofumi surname: Arai fullname: Arai, Hirofumi organization: Department of Psychology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 8 givenname: Chieko surname: Takamiya fullname: Takamiya, Chieko organization: Department of Psychology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 9 givenname: Michio surname: Suzuki fullname: Suzuki, Michio organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan – sequence: 10 givenname: Masayoshi surname: Kurachi fullname: Kurachi, Masayoshi organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23923484$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20800904$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk9r3DAQxUVJaTZpv0LQpfTkjSRbawlKaQn9E0jIoS30JibymGhrS66kDWw-fWV2l0AOTUEgEL_3ZjRvTsiRDx4JOeNsyRlfna-XU9rau4hpKVh5ZO2SNfoFWXDViqrloj4iiwLKireKH5OTlNaMMcG1fkWOBVOMadYsyK9rHG8jeKQ95LylYF1HB7zHIVEoh04RO2dziDT0NEeEPKLPtBSegk9InaeljeCdpcneuYcwlaa8g9fkZQ9Dwjf7-5T8_PL5x8W36urm6-XFp6vKyrbOlQTb6t5qjjUorRTUILFbdRqE7YSQwGUteg6oBALvrZJSigY6paFueFGdknc73ymGPxtM2YwuWRyG8qewSUbJpm61bkUhz_bk5nbEzkzRjRC35jCMArzdA5AsDH0Zi3Xpkau1qBs1c-93nI0hpYi9sS5DdsHnCG4wnJk5I7M2h4zMnJFhrSkZFfnqifxQ4Vnhx52whIP3DqNJ1qG3JaCINpsuuOctPjyxsIMr2cHwG7eY1mETfUnLcJOEYeb7vEHzAvGyO43iq38b_E8HfwGN59qr |
CODEN | PSRSDR |
CitedBy_id | crossref_primary_10_1016_j_glohj_2020_01_004 crossref_primary_10_1016_j_plefa_2023_102604 crossref_primary_10_1016_j_jchromb_2015_05_011 crossref_primary_10_1210_endocr_bqad025 crossref_primary_10_3389_fpsyt_2023_1188452 crossref_primary_10_1016_j_schres_2012_08_014 crossref_primary_10_3389_fncel_2023_1163764 crossref_primary_10_3390_ijms20215257 crossref_primary_10_1515_cpp_2016_0021 crossref_primary_10_1016_j_psychres_2012_02_019 crossref_primary_10_3390_ijms25094824 crossref_primary_10_1016_j_ejphar_2025_177469 crossref_primary_10_1016_j_pnpbp_2024_111011 crossref_primary_10_1111_acps_12388 crossref_primary_10_1016_j_bionps_2024_100089 crossref_primary_10_1177_2156587213488788 crossref_primary_10_1371_journal_pone_0068717 crossref_primary_10_1038_s41537_022_00214_2 crossref_primary_10_3389_fpsyt_2023_1089724 crossref_primary_10_1186_s12888_016_1006_3 crossref_primary_10_3389_fpsyt_2024_1361997 crossref_primary_10_1016_j_plefa_2017_03_006 crossref_primary_10_1016_j_plefa_2023_102578 |
Cites_doi | 10.1016/S0165-1781(99)00051-7 10.1093/schbul/sbi058 10.1016/S0006-3223(02)01397-5 10.1016/0920-9964(94)90014-0 10.1016/S0006-3223(02)01443-9 10.1016/0920-9964(94)90084-1 10.1016/j.schres.2008.01.020 10.1016/S0920-9964(97)00151-5 10.1016/S0278-5846(01)00211-1 10.1016/S0140-6736(05)79168-6 10.1016/S0920-9964(01)00334-6 10.1016/j.plefa.2003.08.010 10.1016/j.schres.2006.11.027 10.1016/S0165-1781(99)00014-1 10.1016/0165-1781(89)90146-7 10.1016/S0006-3223(99)00092-X 10.1016/j.pnpbp.2006.11.013 10.1016/j.psychres.2006.05.025 10.1016/S0920-9964(98)00016-4 10.1016/S0006-3223(00)00986-0 10.1093/oxfordjournals.schbul.a033376 10.1016/0022-3956(95)00001-L 10.1016/S0165-1781(96)02993-9 10.1016/j.schres.2008.09.027 10.1016/S0022-3956(01)00048-6 10.1016/S0165-1781(03)00220-8 10.1093/jn/124.12.2466 10.1093/oxfordjournals.schbul.a007140 10.1016/0165-0327(95)00092-5 10.1016/j.schres.2008.03.009 10.1016/S0022-2275(20)43209-2 10.1016/0920-9964(94)90045-0 10.1016/j.plefa.2008.11.004 10.1016/j.schres.2008.11.025 10.1038/sj.mp.4002000 10.1054/plef.2000.0191 10.1016/j.pscychresns.2008.07.005 10.1007/s00213-004-1924-5 10.1016/0920-9964(94)90046-9 10.1016/j.psychres.2005.09.006 10.1016/j.pnpbp.2003.09.010 10.1016/S0920-9964(02)00284-0 |
ContentType | Journal Article |
Copyright | 2010 Elsevier Ireland Ltd Elsevier Ireland Ltd 2015 INIST-CNRS Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
Copyright_xml | – notice: 2010 Elsevier Ireland Ltd – notice: Elsevier Ireland Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.psychres.2010.07.049 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-7123 |
EndPage | 27 |
ExternalDocumentID | 20800904 23923484 10_1016_j_psychres_2010_07_049 S0165178110004816 1_s2_0_S0165178110004816 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 4.4 457 4G. 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGKA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K UV1 WUQ Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU EFLBG LCYCR ZA5 AAYXX ACLOT CITATION ~HD AGRNS IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c573t-5ac79fc91e3a8988a3a5ed6d9a2cd225a1532f1ae82ea1fc855524ad89a3411e3 |
IEDL.DBID | .~1 |
ISSN | 0165-1781 |
IngestDate | Tue Sep 30 22:48:45 EDT 2025 Mon Jul 21 05:58:51 EDT 2025 Mon Jul 21 09:17:14 EDT 2025 Wed Oct 01 04:10:09 EDT 2025 Thu Apr 24 23:06:31 EDT 2025 Fri Feb 23 02:33:51 EST 2024 Sun Feb 23 10:19:16 EST 2025 Tue Aug 26 16:35:31 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Schizophrenia Essential polyunsaturated fatty acids Phospholipids Cognition Antipsychotic drugs Social function Neuroleptic Psychotropic Polyunsaturated fatty acid Pharmacotherapy Phospholipid Lipids Fatty acids Psychosis Chronic Treatment Antipsychotic Essential fatty acid Predictive factor |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c573t-5ac79fc91e3a8988a3a5ed6d9a2cd225a1532f1ae82ea1fc855524ad89a3411e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 20800904 |
PQID | 854379972 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_854379972 pubmed_primary_20800904 pascalfrancis_primary_23923484 crossref_citationtrail_10_1016_j_psychres_2010_07_049 crossref_primary_10_1016_j_psychres_2010_07_049 elsevier_sciencedirect_doi_10_1016_j_psychres_2010_07_049 elsevier_clinicalkeyesjournals_1_s2_0_S0165178110004816 elsevier_clinicalkey_doi_10_1016_j_psychres_2010_07_049 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2011-03-30 |
PublicationDateYYYYMMDD | 2011-03-30 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-30 day: 30 |
PublicationDecade | 2010 |
PublicationPlace | Kidlington |
PublicationPlace_xml | – name: Kidlington – name: Ireland |
PublicationTitle | Psychiatry research |
PublicationTitleAlternate | Psychiatry Res |
PublicationYear | 2011 |
Publisher | Elsevier Ireland Ltd Elsevier |
Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier |
References | Andreasen (bb0005) 1983 Khan, Evans, Gunna, Scheffer, Parikh, Mahadik (bb0100) 2002; 58 McNamara, Able, Jandacek, Rider, Tso (bb0120) 2009; 107 Evans, Parikh, Khan, Coussons, Buckley, Mahadik (bb0060) 2003; 69 Fenton, Hibbeln, Knable (bb0065) 2000; 47 Maes, Smith, Christophe, Cosyns, Desnyder, Meltzer (bb0110) 1996; 38 Hibbeln (bb0080) 1998; 351 Doris, Wahle, MacDonald, Morris, Coffey, Muir, Blackwood (bb0050) 1998; 31 Meltzer, Li, Kaneda, Ichikawa (bb0130) 2003; 27 Ohara (bb0140) 2007; 31 McNamara, Jandacek, Rider, Tso, Hahn, Richtand, Stanford (bb0125) 2007; 91 Vaddadi, Courtney, Gilleard, Manku, Horrobin (bb0195) 1989; 27 Connor, Neuringer, Lin (bb0040) 1990; 31 Polymeropoulos, Licamele, Volpi, Mack, Mitkus, Carstea, Getoor, Thompson, Lavedan (bb0155) 2009; 108 Andreasen (bb0010) 1983 Peet, Horrobin (bb0145) 2002; 36 Maes, Christophe, Delanghe, Altamura, Neels, Meltzer (bb0105) 1999; 85 Sumiyoshi, Hasegawa, Jayathilake, Meltzer (bb0175) 1997; 69 Yao, van Kammen, Welker (bb0215) 1994; 13 Sumiyoshi, Roy, Kim, Jayathilake, Lee, Sumiyoshi, Meltzer (bb0190) 2004; 177 Elizabeth Sublette, Milak, Hibbeln, Freed, Oquendo, Malone, Parsey, John Mann (bb0055) 2009; 80 Delion, Chalon, Herault, Guilloteau, Besnard, Durand (bb0045) 1994; 124 Arvindakshan, Sitasawad, Debsikdar, Ghate, Evans, Horrobin, Bennet, Ranjekar, Mahadik (bb0020) 2003; 53 Yao, van Kammen, Gurklis (bb0210) 1994; 13 Bennett, Horrobin (bb0030) 2000; 63 Richardson, Allen, Hajnal, Cox, Easton, Puri (bb0170) 2001; 25 Yao, Stanley, Reddy, Keshavan, Pettegrew (bb0200) 2002; 52 Kaddurah-Daouk, McEvoy, Baillie, Lee, Yao, Doraiswamy, Krishnan (bb0095) 2007; 12 Arvindakshan, Ghate, Ranjekar, Evans, Mahadik (bb0015) 2003; 62 Meltzer, McGurk (bb0135) 1999; 25 Matsui, Sumiyoshi, Yuuki, Kato, Kurachi (bb0115) 2006; 143 Ranjekar, Hinge, Hegde, Ghate, Kale, Sitasawad, Wagh, Debsikdar (bb0160) 2003; 121 Hagan, Jones (bb0075) 2005; 31 Chan, Chiu, Lam, Pang, Chow (bb0035) 1999; 87 Condray, Yao, Steinhauer, van Kammen, Reddy, Morrow (bb0220) 2008; 106 Assies, Lieverse, Vreken, Wanders, Dingemans, Linszen (bb0025) 2001; 49 Peet, Laugharne, Rangarajan, Horrobin, Reynolds (bb0150) 1995; 29 Glen, Glen, Horrobin, Vaddadi, Spellman, Morse-Fisher, Ellis (bb0070) 1994; 12 Sumiyoshi, Higuchi, Itoh, Matsui, Arai, Suzuki, Kurachi, Kawasaki (bb0180) 2009; 172 Horrobin (bb0090) 1998; 30 Sumiyoshi, Matsui, Itoh, Higuchi, Arai, Takamiya, Kurachi (bb0185) 2008; 157 Higuchi, Sumiyoshi, Kawasaki, Matsui, Arai, Kurachi (bb0085) 2008; 101 Yao, van Kammen (bb0205) 1994; 11 Reddy, Keshavan, Yao (bb0165) 2004; 30 Horrobin (10.1016/j.psychres.2010.07.049_bb0090) 1998; 30 Yao (10.1016/j.psychres.2010.07.049_bb0205) 1994; 11 Polymeropoulos (10.1016/j.psychres.2010.07.049_bb0155) 2009; 108 Higuchi (10.1016/j.psychres.2010.07.049_bb0085) 2008; 101 Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0190) 2004; 177 Reddy (10.1016/j.psychres.2010.07.049_bb0165) 2004; 30 McNamara (10.1016/j.psychres.2010.07.049_bb0125) 2007; 91 Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0180) 2009; 172 Peet (10.1016/j.psychres.2010.07.049_bb0145) 2002; 36 McNamara (10.1016/j.psychres.2010.07.049_bb0120) 2009; 107 Assies (10.1016/j.psychres.2010.07.049_bb0025) 2001; 49 Chan (10.1016/j.psychres.2010.07.049_bb0035) 1999; 87 Doris (10.1016/j.psychres.2010.07.049_bb0050) 1998; 31 Andreasen (10.1016/j.psychres.2010.07.049_bb0005) 1983 Matsui (10.1016/j.psychres.2010.07.049_bb0115) 2006; 143 Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0185) 2008; 157 Yao (10.1016/j.psychres.2010.07.049_bb0215) 1994; 13 Kaddurah-Daouk (10.1016/j.psychres.2010.07.049_bb0095) 2007; 12 Bennett (10.1016/j.psychres.2010.07.049_bb0030) 2000; 63 Meltzer (10.1016/j.psychres.2010.07.049_bb0135) 1999; 25 Condray (10.1016/j.psychres.2010.07.049_bb0220) 2008; 106 Richardson (10.1016/j.psychres.2010.07.049_bb0170) 2001; 25 Andreasen (10.1016/j.psychres.2010.07.049_bb0010) 1983 Elizabeth Sublette (10.1016/j.psychres.2010.07.049_bb0055) 2009; 80 Connor (10.1016/j.psychres.2010.07.049_bb0040) 1990; 31 Yao (10.1016/j.psychres.2010.07.049_bb0210) 1994; 13 Maes (10.1016/j.psychres.2010.07.049_bb0105) 1999; 85 Khan (10.1016/j.psychres.2010.07.049_bb0100) 2002; 58 Delion (10.1016/j.psychres.2010.07.049_bb0045) 1994; 124 Evans (10.1016/j.psychres.2010.07.049_bb0060) 2003; 69 Peet (10.1016/j.psychres.2010.07.049_bb0150) 1995; 29 Yao (10.1016/j.psychres.2010.07.049_bb0200) 2002; 52 Arvindakshan (10.1016/j.psychres.2010.07.049_bb0015) 2003; 62 Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0175) 1997; 69 Maes (10.1016/j.psychres.2010.07.049_bb0110) 1996; 38 Hibbeln (10.1016/j.psychres.2010.07.049_bb0080) 1998; 351 Glen (10.1016/j.psychres.2010.07.049_bb0070) 1994; 12 Ohara (10.1016/j.psychres.2010.07.049_bb0140) 2007; 31 Vaddadi (10.1016/j.psychres.2010.07.049_bb0195) 1989; 27 Arvindakshan (10.1016/j.psychres.2010.07.049_bb0020) 2003; 53 Hagan (10.1016/j.psychres.2010.07.049_bb0075) 2005; 31 Meltzer (10.1016/j.psychres.2010.07.049_bb0130) 2003; 27 Ranjekar (10.1016/j.psychres.2010.07.049_bb0160) 2003; 121 Fenton (10.1016/j.psychres.2010.07.049_bb0065) 2000; 47 |
References_xml | – volume: 31 start-page: 830 year: 2005 end-page: 853 ident: bb0075 article-title: Predicting drug efficacy for cognitive deficits in schizophrenia publication-title: Schizophrenia Bulletin – volume: 157 start-page: 87 year: 2008 end-page: 93 ident: bb0185 article-title: Essential polyunsaturated fatty acids and social cognition in schizophrenia publication-title: Psychiatry Research – volume: 27 start-page: 1159 year: 2003 end-page: 1172 ident: bb0130 article-title: Serotonin receptors: their key role in drugs to treat schizophrenia publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry – volume: 121 start-page: 109 year: 2003 end-page: 122 ident: bb0160 article-title: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients publication-title: Psychiatry Research – volume: 63 start-page: 47 year: 2000 end-page: 59 ident: bb0030 article-title: Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update publication-title: Prostaglandins Leukotriene and Essential Fatty Acids – volume: 172 start-page: 180 year: 2009 end-page: 183 ident: bb0180 article-title: Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA publication-title: Psychiatry Research Neuroimaging – volume: 31 start-page: 237 year: 1990 end-page: 247 ident: bb0040 article-title: Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys publication-title: Jounral of Lipid Research – volume: 36 start-page: 7 year: 2002 end-page: 18 ident: bb0145 article-title: A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms publication-title: Journal of Psychiatry Research – volume: 107 start-page: 150 year: 2009 end-page: 157 ident: bb0120 article-title: Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis publication-title: Schizophrenia Research – volume: 25 start-page: 233 year: 1999 end-page: 255 ident: bb0135 article-title: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia publication-title: Schizophrenia Bulletin – volume: 31 start-page: 469 year: 2007 end-page: 474 ident: bb0140 article-title: The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry – volume: 30 start-page: 193 year: 1998 end-page: 208 ident: bb0090 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research – volume: 25 start-page: 1513 year: 2001 end-page: 1521 ident: bb0170 article-title: Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry – volume: 124 start-page: 2466 year: 1994 end-page: 2476 ident: bb0045 article-title: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats publication-title: Journal of Nutrition – volume: 69 start-page: 113 year: 1997 end-page: 121 ident: bb0175 article-title: Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine publication-title: Psychiatry Research – volume: 47 start-page: 8 year: 2000 end-page: 21 ident: bb0065 article-title: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia publication-title: Biological Psychiatry – volume: 27 start-page: 313 year: 1989 end-page: 323 ident: bb0195 article-title: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia publication-title: Psychiatry Research – volume: 58 start-page: 1 year: 2002 end-page: 10 ident: bb0100 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophrenia Research – volume: 143 start-page: 179 year: 2006 end-page: 187 ident: bb0115 article-title: Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket publication-title: Psychiatry Research – volume: 29 start-page: 227 year: 1995 end-page: 232 ident: bb0150 article-title: Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients publication-title: Jounral of Psychiatry Research – volume: 62 start-page: 195 year: 2003 end-page: 204 ident: bb0015 article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia publication-title: Schizophrenia Research – volume: 91 start-page: 37 year: 2007 end-page: 50 ident: bb0125 article-title: Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications publication-title: Schizophrenia Research – volume: 101 start-page: 320 year: 2008 end-page: 330 ident: bb0085 article-title: Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300 publication-title: Schizophrenia Research – volume: 13 start-page: 217 year: 1994 end-page: 226 ident: bb0215 article-title: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition publication-title: Schizophrenia Research – volume: 53 start-page: 56 year: 2003 end-page: 64 ident: bb0020 article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients publication-title: Biological Psychiatry – year: 1983 ident: bb0005 article-title: Scale for the Assessment of Negative Symptoms (SANS) – volume: 69 start-page: 393 year: 2003 end-page: 399 ident: bb0060 article-title: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment publication-title: Prostaglandins Leukotrienes and Essent Fatty Acids – volume: 85 start-page: 275 year: 1999 end-page: 291 ident: bb0105 article-title: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients publication-title: Psychiatry Research – volume: 106 start-page: 13 year: 2008 end-page: 28 ident: bb0220 article-title: Semantic memory in schizophrenia: association with cell membrane essential fatty acids publication-title: Schizophrenia Research – volume: 87 start-page: 169 year: 1999 end-page: 181 ident: bb0035 article-title: A breakdown of event schemas in patients with schizophrenia: an examination of their script for dining at restaurants publication-title: Psychiatry Research – year: 1983 ident: bb0010 article-title: Scale for the Assessment of Positive Symptoms (SAPS) – volume: 12 start-page: 934 year: 2007 end-page: 945 ident: bb0095 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Molecular Psychiatry – volume: 12 start-page: 53 year: 1994 end-page: 61 ident: bb0070 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophrenia Research – volume: 13 start-page: 227 year: 1994 end-page: 232 ident: bb0210 article-title: Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures publication-title: Schizophrenia Research – volume: 11 start-page: 209 year: 1994 end-page: 216 ident: bb0205 article-title: Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity publication-title: Schizophrenia Research – volume: 351 start-page: 1213 year: 1998 ident: bb0080 article-title: Fish consumption and major depression publication-title: Lancet – volume: 52 start-page: 823 year: 2002 end-page: 830 ident: bb0200 article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites publication-title: Biological Psychiatry – volume: 31 start-page: 185 year: 1998 end-page: 196 ident: bb0050 article-title: Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia publication-title: Schizophrenia Research – volume: 30 start-page: 901 year: 2004 end-page: 911 ident: bb0165 article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline publication-title: Schizophrenia Bulletin – volume: 177 start-page: 79 year: 2004 end-page: 83 ident: bb0190 article-title: Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia publication-title: Psychopharmacology (Berl) – volume: 80 start-page: 57 year: 2009 end-page: 64 ident: bb0055 article-title: Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression publication-title: Prostaglandins Leukotriene Essential Fatty Acids – volume: 38 start-page: 35 year: 1996 end-page: 46 ident: bb0110 article-title: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids publication-title: Journal of Affective Disorders – volume: 49 start-page: 510 year: 2001 end-page: 522 ident: bb0025 article-title: Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group publication-title: Biological Psychiatry – volume: 108 start-page: 134 year: 2009 end-page: 142 ident: bb0155 article-title: Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia publication-title: Schizophrenia Research – volume: 87 start-page: 169 year: 1999 ident: 10.1016/j.psychres.2010.07.049_bb0035 article-title: A breakdown of event schemas in patients with schizophrenia: an examination of their script for dining at restaurants publication-title: Psychiatry Research doi: 10.1016/S0165-1781(99)00051-7 – volume: 31 start-page: 830 year: 2005 ident: 10.1016/j.psychres.2010.07.049_bb0075 article-title: Predicting drug efficacy for cognitive deficits in schizophrenia publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/sbi058 – volume: 52 start-page: 823 year: 2002 ident: 10.1016/j.psychres.2010.07.049_bb0200 article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(02)01397-5 – volume: 11 start-page: 209 year: 1994 ident: 10.1016/j.psychres.2010.07.049_bb0205 article-title: Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90014-0 – year: 1983 ident: 10.1016/j.psychres.2010.07.049_bb0010 – volume: 53 start-page: 56 year: 2003 ident: 10.1016/j.psychres.2010.07.049_bb0020 article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(02)01443-9 – volume: 12 start-page: 53 year: 1994 ident: 10.1016/j.psychres.2010.07.049_bb0070 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90084-1 – volume: 101 start-page: 320 year: 2008 ident: 10.1016/j.psychres.2010.07.049_bb0085 article-title: Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300 publication-title: Schizophrenia Research doi: 10.1016/j.schres.2008.01.020 – volume: 30 start-page: 193 year: 1998 ident: 10.1016/j.psychres.2010.07.049_bb0090 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(97)00151-5 – volume: 25 start-page: 1513 year: 2001 ident: 10.1016/j.psychres.2010.07.049_bb0170 article-title: Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry doi: 10.1016/S0278-5846(01)00211-1 – volume: 351 start-page: 1213 year: 1998 ident: 10.1016/j.psychres.2010.07.049_bb0080 article-title: Fish consumption and major depression publication-title: Lancet doi: 10.1016/S0140-6736(05)79168-6 – volume: 58 start-page: 1 year: 2002 ident: 10.1016/j.psychres.2010.07.049_bb0100 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(01)00334-6 – volume: 69 start-page: 393 year: 2003 ident: 10.1016/j.psychres.2010.07.049_bb0060 article-title: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment publication-title: Prostaglandins Leukotrienes and Essent Fatty Acids doi: 10.1016/j.plefa.2003.08.010 – volume: 91 start-page: 37 year: 2007 ident: 10.1016/j.psychres.2010.07.049_bb0125 article-title: Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications publication-title: Schizophrenia Research doi: 10.1016/j.schres.2006.11.027 – volume: 85 start-page: 275 year: 1999 ident: 10.1016/j.psychres.2010.07.049_bb0105 article-title: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients publication-title: Psychiatry Research doi: 10.1016/S0165-1781(99)00014-1 – volume: 27 start-page: 313 year: 1989 ident: 10.1016/j.psychres.2010.07.049_bb0195 article-title: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia publication-title: Psychiatry Research doi: 10.1016/0165-1781(89)90146-7 – volume: 47 start-page: 8 year: 2000 ident: 10.1016/j.psychres.2010.07.049_bb0065 article-title: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(99)00092-X – volume: 31 start-page: 469 year: 2007 ident: 10.1016/j.psychres.2010.07.049_bb0140 article-title: The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry doi: 10.1016/j.pnpbp.2006.11.013 – volume: 157 start-page: 87 year: 2008 ident: 10.1016/j.psychres.2010.07.049_bb0185 article-title: Essential polyunsaturated fatty acids and social cognition in schizophrenia publication-title: Psychiatry Research doi: 10.1016/j.psychres.2006.05.025 – volume: 31 start-page: 185 year: 1998 ident: 10.1016/j.psychres.2010.07.049_bb0050 article-title: Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(98)00016-4 – volume: 49 start-page: 510 year: 2001 ident: 10.1016/j.psychres.2010.07.049_bb0025 article-title: Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group publication-title: Biological Psychiatry doi: 10.1016/S0006-3223(00)00986-0 – volume: 25 start-page: 233 year: 1999 ident: 10.1016/j.psychres.2010.07.049_bb0135 article-title: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia publication-title: Schizophrenia Bulletin doi: 10.1093/oxfordjournals.schbul.a033376 – volume: 29 start-page: 227 year: 1995 ident: 10.1016/j.psychres.2010.07.049_bb0150 article-title: Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients publication-title: Jounral of Psychiatry Research doi: 10.1016/0022-3956(95)00001-L – volume: 69 start-page: 113 year: 1997 ident: 10.1016/j.psychres.2010.07.049_bb0175 article-title: Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine publication-title: Psychiatry Research doi: 10.1016/S0165-1781(96)02993-9 – volume: 107 start-page: 150 year: 2009 ident: 10.1016/j.psychres.2010.07.049_bb0120 article-title: Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis publication-title: Schizophrenia Research doi: 10.1016/j.schres.2008.09.027 – volume: 36 start-page: 7 year: 2002 ident: 10.1016/j.psychres.2010.07.049_bb0145 article-title: A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms publication-title: Journal of Psychiatry Research doi: 10.1016/S0022-3956(01)00048-6 – volume: 121 start-page: 109 year: 2003 ident: 10.1016/j.psychres.2010.07.049_bb0160 article-title: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients publication-title: Psychiatry Research doi: 10.1016/S0165-1781(03)00220-8 – volume: 124 start-page: 2466 year: 1994 ident: 10.1016/j.psychres.2010.07.049_bb0045 article-title: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats publication-title: Journal of Nutrition doi: 10.1093/jn/124.12.2466 – volume: 30 start-page: 901 year: 2004 ident: 10.1016/j.psychres.2010.07.049_bb0165 article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline publication-title: Schizophrenia Bulletin doi: 10.1093/oxfordjournals.schbul.a007140 – volume: 38 start-page: 35 year: 1996 ident: 10.1016/j.psychres.2010.07.049_bb0110 article-title: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids publication-title: Journal of Affective Disorders doi: 10.1016/0165-0327(95)00092-5 – year: 1983 ident: 10.1016/j.psychres.2010.07.049_bb0005 – volume: 106 start-page: 13 year: 2008 ident: 10.1016/j.psychres.2010.07.049_bb0220 article-title: Semantic memory in schizophrenia: association with cell membrane essential fatty acids publication-title: Schizophrenia Research doi: 10.1016/j.schres.2008.03.009 – volume: 31 start-page: 237 year: 1990 ident: 10.1016/j.psychres.2010.07.049_bb0040 article-title: Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys publication-title: Jounral of Lipid Research doi: 10.1016/S0022-2275(20)43209-2 – volume: 13 start-page: 217 year: 1994 ident: 10.1016/j.psychres.2010.07.049_bb0215 article-title: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90045-0 – volume: 80 start-page: 57 year: 2009 ident: 10.1016/j.psychres.2010.07.049_bb0055 article-title: Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression publication-title: Prostaglandins Leukotriene Essential Fatty Acids doi: 10.1016/j.plefa.2008.11.004 – volume: 108 start-page: 134 year: 2009 ident: 10.1016/j.psychres.2010.07.049_bb0155 article-title: Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia publication-title: Schizophrenia Research doi: 10.1016/j.schres.2008.11.025 – volume: 12 start-page: 934 year: 2007 ident: 10.1016/j.psychres.2010.07.049_bb0095 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Molecular Psychiatry doi: 10.1038/sj.mp.4002000 – volume: 63 start-page: 47 year: 2000 ident: 10.1016/j.psychres.2010.07.049_bb0030 article-title: Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update publication-title: Prostaglandins Leukotriene and Essential Fatty Acids doi: 10.1054/plef.2000.0191 – volume: 172 start-page: 180 year: 2009 ident: 10.1016/j.psychres.2010.07.049_bb0180 article-title: Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA publication-title: Psychiatry Research Neuroimaging doi: 10.1016/j.pscychresns.2008.07.005 – volume: 177 start-page: 79 year: 2004 ident: 10.1016/j.psychres.2010.07.049_bb0190 article-title: Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-004-1924-5 – volume: 13 start-page: 227 year: 1994 ident: 10.1016/j.psychres.2010.07.049_bb0210 article-title: Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures publication-title: Schizophrenia Research doi: 10.1016/0920-9964(94)90046-9 – volume: 143 start-page: 179 year: 2006 ident: 10.1016/j.psychres.2010.07.049_bb0115 article-title: Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket publication-title: Psychiatry Research doi: 10.1016/j.psychres.2005.09.006 – volume: 27 start-page: 1159 year: 2003 ident: 10.1016/j.psychres.2010.07.049_bb0130 article-title: Serotonin receptors: their key role in drugs to treat schizophrenia publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry doi: 10.1016/j.pnpbp.2003.09.010 – volume: 62 start-page: 195 year: 2003 ident: 10.1016/j.psychres.2010.07.049_bb0015 article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia publication-title: Schizophrenia Research doi: 10.1016/S0920-9964(02)00284-0 |
SSID | ssj0002199 |
Score | 2.102059 |
Snippet | Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has... Abstract Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 23 |
SubjectTerms | Adult Adult and adolescent clinical studies Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Antipsychotic drugs Biological and medical sciences Cell Membrane - drug effects Cell Membrane - metabolism Chronic Disease Cognition Erythrocytes - drug effects Erythrocytes - metabolism Erythrocytes - pathology Essential polyunsaturated fatty acids Fatty Acids - metabolism Female Humans Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Phospholipids Predictive Value of Tests Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Schizophrenia Schizophrenia - drug therapy Schizophrenia - metabolism Schizophrenia - pathology Social function Statistics as Topic |
Title | Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165178110004816 https://www.clinicalkey.es/playcontent/1-s2.0-S0165178110004816 https://dx.doi.org/10.1016/j.psychres.2010.07.049 https://www.ncbi.nlm.nih.gov/pubmed/20800904 https://www.proquest.com/docview/854379972 |
Volume | 186 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1872-7123 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1872-7123 dateEnd: 20191231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: ACRLP dateStart: 19950131 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1872-7123 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1872-7123 dateEnd: 20191231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: AIKHN dateStart: 19950131 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1872-7123 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002199 issn: 0165-1781 databaseCode: AKRWK dateStart: 19790701 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9KC2MwRruvut2CHvaqxNZHLD2WspJtpC9bIW9ClmVI6ZwQuw972d--UySnLdvYWMEvNjosn-50d9bv7gDe28pyXjFJq1oJKpT01BbSUTR1mis1taUL-c7zy-nsSnxayMUenA-5MAFWmfb-uKdvd-v0ZJK4OVkvl5MvIRGnCImSsehJKLsdqn-hTI9_3ME8WOwhGQbTMPpelvD1eIsoxrA2QbzKcR5qav7eQD1b2w7Z1sR-F392SLeG6eIQniePkpzFSR_Bnm9fwJN5OjN_CYu5_4YhcetJY_v-O7FuWZObgBXqiMWLrDdhLMbeZNWQHfCcbCJ61pNlS1wsoUu6-xC9V3B18eHr-YymfgrUyZL3VFpX6sbpwnOrtFKWW-nraa0tczXqNS4SZ01hvWLeFo1TUkombK20RVuHVK9hv121_hiIL5oaydHsVUqI2mvNfM7xLgREjeAZyIGJxqVi46HnxY0ZUGXXZmC-Ccw3eWmQ-RlMdnTrWG7jrxTlsEZmSCbF7c-gRfg_St8lLe5MYTpmcvOLpGWgd5QPhPWf3jp6IEi7z2ToqXKhRAZkkCyDqh7Ob1BEVredUTIUj9Qly-BNlLg74uD461ycPGJmp_A0_jDnlOdvYb_f3Pp36HH11WirUiM4OPv4eXb5E0njLE8 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7SDbSFEvqu2zTVoVdnbT3W0jGEhk2T3UsT2JuQZRk2pN5l7Rz67ztayW5CW1JS8MVGg-XRaB7WNzMAn01pGCupSMtK8pRL4VKTC5uiqVNMyokprM93ns0n00v-dSEWO3Dc58J4WGXU_UGnb7V1fDKO3Byvl8vxN5-Ik_tEyVD0ZPIIdrlAnTyC3aPTs-l8UMg0tJH041NPcCtR-OpwCyrGyDaivIrDzJfV_LONerY2LXKuDi0v_u6Tbm3TyXPYi04lOQrzfgE7rnkJj2fx2PwVLGbuO0bFjSO16bofxNhlRa49XKglBi-y3vixGH6TVU0G7DnZBACtI8uG2FBFl7S3UXqv4fLky8XxNI0tFVIrCtalwthC1VbljhmppDTMCFdNKmWorXBr4zoxWufGSepMXlsphKDcVFIZNHdI9QZGzapx74C4vK6QHC1fKTmvnFLUZQzvfExUc5aA6Jmobaw37tteXOseWHale-Zrz3ydFRqZn8B4oFuHihv3UhT9Guk-nxQ1oEaj8DBK18aN3Opct1Rn-jdhS0ANlHfk9Z_eenBHkIbPpOisMi55AqSXLI273R_hoIisblotha8fqQqawNsgcb-Ive-vMv7-P2b2CZ5ML2bn-vx0fvYBnob_5yxl2T6Mus2N-4gOWFcexA32E2KZLvo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Membrane+fatty+acid+levels+as+a+predictor+of+treatment+response+in+chronic+schizophrenia&rft.jtitle=Psychiatry+research&rft.au=Sumiyoshi%2C+Tomiki&rft.au=Higuchi%2C+Yuko&rft.au=Matsui%2C+Mie&rft.au=Itoh%2C+Hiroko&rft.date=2011-03-30&rft.pub=Elsevier+Ireland+Ltd&rft.issn=0165-1781&rft.volume=186&rft.issue=1&rft.spage=23&rft.epage=27&rft_id=info:doi/10.1016%2Fj.psychres.2010.07.049&rft.externalDocID=S0165178110004816 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01651781%2FS0165178111X00033%2Fcov150h.gif |